000726978 000__ 05867cam\a2200493Ii\4500
000726978 001__ 726978
000726978 005__ 20230306140846.0
000726978 006__ m\\\\\o\\d\\\\\\\\
000726978 007__ cr\cn\nnnunnun
000726978 008__ 150511s2015\\\\sz\\\\\\ob\\\\000\0\eng\d
000726978 019__ $$a914151079
000726978 020__ $$a9783319175904$$qelectronic book
000726978 020__ $$a3319175904$$qelectronic book
000726978 020__ $$z9783319175898
000726978 0247_ $$a10.1007/978-3-319-17590-4$$2doi
000726978 035__ $$aSP(OCoLC)ocn908685755
000726978 035__ $$aSP(OCoLC)908685755$$z(OCoLC)914151079
000726978 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dIDEBK$$dYDXCP$$dE7B$$dNUI$$dCOO$$dEBLCP$$dDEBSZ$$dCDX
000726978 043__ $$aaw-----
000726978 049__ $$aISEA
000726978 050_4 $$aRS67.M628
000726978 08204 $$a615.1093$$223
000726978 1001_ $$aAl-Essa, Reem K.,$$eauthor.
000726978 24510 $$aPharmaceutical regulatory environment$$h[electronic resource] :$$bchallenges and opportunities in the Gulf Region /$$cReem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.
000726978 264_1 $$aCham :$$bAdis,$$c2015.
000726978 300__ $$a1 online resource
000726978 336__ $$atext$$btxt$$2rdacontent
000726978 337__ $$acomputer$$bc$$2rdamedia
000726978 338__ $$aonline resource$$bcr$$2rdacarrier
000726978 504__ $$aIncludes bibliographical references.
000726978 5050_ $$a1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
000726978 506__ $$aAccess limited to authorized users.
000726978 520__ $$aThe Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients? access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region. Reem Al-Essa BPharm MSc PhD was the Drug Registration and Release Superintendent, Kuwait Ministry of Health, Drug and Food Control Department, for 12 years during which time she completed her MBA with distinction. She later undertook the EU2P MSc in Pharmacovigilance and Pharmacoepidemiology. Dr Al-Essa has published six journal articles and abstracts related to pharmaceutical regulation in the Gulf region. Mohammed Hamdan Al-Rubaie BPharm MSc PhD is the Director of Drug Control, Directorate General of Pharmaceutical affairs and Drug Control, Oman Ministry of Health.He is a member of the GCC Central Registration Committee, and actively involved in many other GCC committees and working groups for the drafting of the GCC pharmaceutical regulations and policies. Dr Al-Rubaie was instrumental in forming the Pharmaceutical society in Oman and chaired it from 2010-2011. Stuart Walker BSc, PhD, MFPM FRSC FIBiol, FRCPath, is the Founder of the Centre for Medicines Research International, the Centre for Innovation in Regulatory Science and Professor of Pharmaceutical Medicine, University of Wales, Cardiff. During his research career in academia & industry, he has supervised many PhD programmes in clinical development, regulatory policies, the benefit/risk assessment of medicines and health technology assessment, co-authored 280 research papers and edited 25 books. He is frequently involved in the organisation of international meetings on key issues that concern the regulatory review of medicines and has lectured extensively throughout Europe, the USA, the Asia-Pacific Region, Latin America and the Middle East. Sam Salek PhD RPh FFPM MRPSGB MCMS FESCP is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek?s research focuses mainly on four areas: development and application of patient-reported outcome measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 19 books and 600 journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.
000726978 588__ $$aOnline resource; title from PDF title page (viewed May 13, 2015)
000726978 650_0 $$aPharmacy$$xLaw and legislation$$zMiddle East.
000726978 650_0 $$aDrugs$$xLaw and legislation$$zMiddle East.
000726978 7001_ $$aAl-Rubaie, Mohammed,$$eauthor.
000726978 7001_ $$aWalker, Stuart,$$eauthor.
000726978 7001_ $$aSalek, Sam,$$eauthor.
000726978 77608 $$iPrint version:$$z9783319175898
000726978 852__ $$bebk
000726978 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-17590-4$$zOnline Access$$91397441.1
000726978 909CO $$ooai:library.usi.edu:726978$$pGLOBAL_SET
000726978 980__ $$aEBOOK
000726978 980__ $$aBIB
000726978 982__ $$aEbook
000726978 983__ $$aOnline
000726978 994__ $$a92$$bISE